{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T10:46:18Z","timestamp":1791888378285,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2011,5,1]],"date-time":"2011-05-01T00:00:00Z","timestamp":1304208000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Human Pathology"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1016\/j.humpath.2010.09.012","type":"journal-article","created":{"date-parts":[[2011,2,3]],"date-time":"2011-02-03T09:15:29Z","timestamp":1296724529000},"page":"719-726","source":"Crossref","is-referenced-by-count":19,"title":["The immunohistochemical staining pattern of Gab2 correlates with distinct stages of chronic myeloid leukemia"],"prefix":"10.1016","volume":"42","author":[{"given":"Konrad","family":"Aumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Lassmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Sch\u00f6pflin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette M.","family":"May","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franziska U.","family":"W\u00f6hrle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelius F.","family":"Waller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter","family":"Hauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Werner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilman","family":"Brummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.humpath.2010.09.012_bb0005","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2010.09.012_bb0010","article-title":"Tumours of haematopoietic and lymphoid tissue","volume":"Vol. 4","author":"Swerdlow","year":"2008"},{"key":"10.1016\/j.humpath.2010.09.012_bb0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.humpath.2010.09.012_bb0020","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.humpath.2010.09.012_bb0025","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1478-811X-7-22","article-title":"Function, regulation and pathological roles of the Gab\/DOS docking proteins","volume":"7","author":"Wohrle","year":"2009","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.humpath.2010.09.012_bb0030","doi-asserted-by":"crossref","first-page":"16421","DOI":"10.1074\/jbc.272.26.16421","article-title":"Characterization of two SHP-2\u2013associated binding proteins and potential substrates in hematopoietic cells","volume":"272","author":"Gu","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2010.09.012_bb0035","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/S1097-2765(00)80288-9","article-title":"Cloning of p97\/Gab2, the major SHP2-binding protein in hematopoietic cells, reveals a novel pathway for cytokine-induced gene activation","volume":"2","author":"Gu","year":"1998","journal-title":"Mol Cell"},{"key":"10.1016\/j.humpath.2010.09.012_bb0040","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1038\/emboj.2008.159","article-title":"Phosphorylation-dependent binding of 14-3-3 terminates signalling by the Gab2 docking protein","volume":"27","author":"Brummer","year":"2008","journal-title":"EMBO J"},{"key":"10.1016\/j.humpath.2010.09.012_bb0045","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.str.2009.05.003","article-title":"How to Grb2 a Gab","volume":"17","author":"Wohrle","year":"2009","journal-title":"Structure"},{"key":"10.1016\/j.humpath.2010.09.012_bb0050","doi-asserted-by":"crossref","first-page":"15943","DOI":"10.1074\/jbc.272.25.15943","article-title":"Characterization of a novel tyrosine phosphorylated 100-kDa protein that binds to SHP-2 and phosphatidylinositol 3\u2032-kinase in myeloid cells","volume":"272","author":"Carlberg","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.humpath.2010.09.012_bb0055","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V93.8.2578","article-title":"Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase","volume":"93","author":"Lecoq-Lafon","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2010.09.012_bb0060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood.V93.6.1809.406k35_1809_1816","article-title":"Gab-family adapter proteins act downstream of cytokine and growth factor receptors and T- and B-cell antigen receptors","volume":"93","author":"Nishida","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2010.09.012_bb0065","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.humpath.2010.09.012_bb0070","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1182\/blood.V99.10.3547","article-title":"Imatinib mesylate (STI571) therapy for Philadelphia chromosome\u2013positive chronic myelogenous leukemia in blast phase","volume":"99","author":"Kantarjian","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2010.09.012_bb0075","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2010.09.012_bb0080","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2010.09.012_bb0085","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.humpath.2010.09.012_bb0090","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"issue":"Suppl 3","key":"10.1016\/j.humpath.2010.09.012_bb0095","first-page":"S49","article-title":"Analysis and validation of prognostic factors for CML. German CML Study Group","volume":"17","author":"Hasford","year":"1996","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.humpath.2010.09.012_bb0100","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1046\/j.1365-2141.1997.102652.x","article-title":"Comparative analysis of the impact of risk profile and of drug therapy on survival in CML using Sokal's index and a new score. German chronic myeloid leukaemia (CML)\u2013Study Group","volume":"97","author":"Hehlmann","year":"1997","journal-title":"Br J Haematol"},{"key":"10.1016\/j.humpath.2010.09.012_bb0105","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1182\/blood-2009-03-212969","article-title":"The derivation of diagnostic markers of chronic myeloid leukemia progression from microarray data","volume":"114","author":"Oehler","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2010.09.012_bb0110","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.humpath.2010.09.012_bb0115","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2010.09.012_bb0120","series-title":"An Atlas of Malignant Haematopathology: Cytology, Histology and Cytogenetics","first-page":"387","author":"Mufti","year":"1996"},{"key":"10.1016\/j.humpath.2010.09.012_bb0125","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.molcel.2004.11.003","article-title":"Transcriptional regulation of AKT activation by E2F","volume":"16","author":"Chaussepied","year":"2004","journal-title":"Mol Cell"},{"key":"10.1016\/j.humpath.2010.09.012_bb0130","doi-asserted-by":"crossref","first-page":"5175","DOI":"10.1038\/sj.onc.1205522","article-title":"The docking protein Gab2 is overexpressed and estrogen regulated in human breast cancer","volume":"21","author":"Daly","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.humpath.2010.09.012_bb0135","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/BJ20041523","article-title":"Activated STAT5 proteins induce activation of the PI 3-kinase\/Akt and Ras\/MAPK pathways via the Gab2 scaffolding adapter","volume":"390","author":"Nyga","year":"2005","journal-title":"Biochem J"},{"key":"10.1016\/j.humpath.2010.09.012_bb0140","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1128\/JVI.02365-07","article-title":"Interaction between simian virus 40 large T antigen and insulin receptor substrate 1 is disrupted by the K1 mutation, resulting in the loss of large T antigen-mediated phosphorylation of Akt","volume":"82","author":"Yu","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.humpath.2010.09.012_bb0145","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","article-title":"Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)","volume":"107","author":"Scherr","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.humpath.2010.09.012_bb0150","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1128\/MCB.19.3.1784","article-title":"The Gab1 PH domain is required for localization of Gab1 at sites of cell-cell contact and epithelial morphogenesis downstream from the met receptor tyrosine kinase","volume":"19","author":"Maroun","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.humpath.2010.09.012_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/84683","article-title":"Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase","volume":"7","author":"Vigneri","year":"2001","journal-title":"Nat Med"},{"key":"10.1016\/j.humpath.2010.09.012_bb0160","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/leu.2008.367","article-title":"Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD34+ chronic myeloid leukaemia cells","volume":"23","author":"Allan","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.humpath.2010.09.012_bb0165","doi-asserted-by":"crossref","first-page":"29691","DOI":"10.1074\/jbc.M309371200","article-title":"ERK1\/2 associates with the c-Met\u2013binding domain of growth factor receptor-bound protein 2 (Grb2)\u2013associated binder-1 (Gab1): role in ERK1\/2 and early growth response factor\u20131 (Egr-1) nuclear accumulation","volume":"279","author":"Osawa","year":"2004","journal-title":"J Biol Chem"}],"container-title":["Human Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817710003709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0046817710003709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T07:02:30Z","timestamp":1592290950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0046817710003709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["S0046817710003709"],"URL":"https:\/\/doi.org\/10.1016\/j.humpath.2010.09.012","relation":{},"ISSN":["0046-8177"],"issn-type":[{"value":"0046-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2011,5]]}}}